Novo Nordisk A/S: Cagrisema Demonstrated 23% Weight Loss In An Open-Label Head-To-Head REDEFINE 4 Trial In People With Obesity, The Primary Endpoint Was Not Achieved | Hoş geldiňiz! | Slzii.com | Habarlar, web, sosial ulgam, oýunlar, güýmenje, baglanyşyklar we gurallary gözläň

Adingüklemek

Slzii.com Gözlemek

Habarlar

Has köp Habarlar >>

Slzii.com Webde gözläň

Slzii.com Sosial ulgam

Android programmasy

Sosial ulgam >>

Näme edýärsiň?

0.023393154144287

Hoş geldiňiz!
Hoş geldiňiz!

Habarlar, web, sosial ulgam, oýunlar, güýmenje, baglanyşyklar we gurallary gözläň
(MENAFN - GlobeNewsWire - Nasdaq) CagriSema achieved 23% weight loss after 84 weeks of treatment CagriSema 2.4/2.4 mg did not meet the prima...
Sosial ulgam, onlaýn jemgyýet, dostlary Edüklemek, aragatnaşyk gurmak, CLIARD jaň ediň, CLILICH-iň birikdirilen, sosial programma, aragatnaşyk ýeri, jemgyýetçilik platformasyny, jemgyýetçilik sahypasy, Torpordsent bilen tanyşyň